Tarsus Pharmaceuticals, Inc. (Nasdaq: TARS), a biopharmaceutical company specializing in ophthalmic therapeutics, has been maintained at a Buy rating by HC Wainwright & Co., who raised the price target from $40 to $44. 

$TARS closed at $17.15 on Monday, the revised price target indicates a potential upside of $26.85 or about 156.65% based on the investment banking firm's analysis.

Vicor Corporation (Nasdaq: VICR), a leading provider of advanced power modules and systems, was maintained at a Buy rating by Needham, accompanied by a raised price target from $55 to $65.

With $VICR closing at $55.35 on Monday, the adjusted price target suggests a potential upside of $9.65 or about 17.43% according to the brokerage firm's perspective.

Syndax Pharmaceuticals, Inc. (Nasdaq: SNDX), a clinical-stage biopharmaceutical company focused on developing therapies for cancer patients, was also maintained at a Buy rating by BTIG, who raised the price target from $34 to $35.

Despite closing at $21.00 on Monday, the updated price target reflects a potential upside of $14.00 or approximately 66.67% for $SNDX, based on BTIG's assessment.

EnLink Midstream, LLC (NYSE: ENLC), a leading midstream energy services company, received coverage initiation from UBS with a Buy rating and a price target of $14.

Based on Monday's closing price of $10.06, the initiation price target suggests a potential upside of $3.94 or about 39.10% for $ENLC, according to the financial services firm's view.

Amazon.com, Inc. (Nasdaq: AMZN), a global e-commerce and technology giant, was maintained at a Buy rating by Roth MKM, with the price target raised from $130 to $155.

Despite closing at $127.33 on Monday, the adjusted price target suggests a potential upside of $27.67 or about 21.73% for $AMZN, based on the investment firm's analysis.

UFP Technologies, Inc. (Nasdaq: UFPT), a leading designer and manufacturer of innovative packaging and component solutions, was also maintained at a Buy rating by Lake Street, accompanied by a raised price target from $171 to $222.

With $UFPT closing at $188.73 on Monday, the updated price target implies a potential upside of $33.27 or approximately 17.74% based on the financial advisory firm's assessment.

Penumbra, Inc. (NYSE: PEN), a global healthcare company focused on innovative medical devices, was maintained at a Buy rating by Deutsche Bank, who raised the price target from $325 to $376.

Based on Monday's closing price of $329.26, the adjusted price target suggests a potential upside of $46.74 or about 14.20% for $PEN, according to the investment firm's analysis.

Please note that the potential upsides mentioned for these companies are based on the assessments and recommendations of the respective brokerage/investment firms, reflecting their outlook on the future performance of each company. It is important for investors to conduct their own research and consider other factors before making any investment decisions.

THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY OR DIGITAL ASSET. Please consult with a professional investment advisor before purchasing or selling any securities viewed on or mentioned herein. (Read Full Disclaimer)